Skip to main content

Table 2 Pathogens and antibiotic treatment of patients with VAP caused by A. baumannii

From: Prognostic factors associated with mortality of drug-resistant Acinetobacter baumannii ventilator-associated pneumonia

Variables

All cases

Survivors

Non-survivors

P value

( N= 337)

( N= 174)

( N= 163)

Pathogens

    

Single microbial

180 (53.4)

98 (56.3)

82 (50.3)

0.269

Polymicrobial

157 (46.6)

76 (43.7)

81 (49.7)

P. aeruginosa

76 (22.2)

32 (18.5)

44 (27.0)

0.063

MRSA

49 (14.5)

18 (10.3)

31 (19.0)

0.024

K. pneumoniae

19 (5.6)

9 (5.2)

10 (6.1)

0.702

 Othersa

29 (8.6)

19 (10.9)

10 (6.1)

0.118

Groups of A. baumannii

    

 DS

33 (9.8)

26 (14.9)

7 (4.3)

<0.001

 MDR

72 (21.4)

49 (28.2)

23 (14.1)

 XDR

220 (65.3)

95 (54.6)

125 (76.7)

 PDR

12 (3.6)

4 (2.3)

8 (4.9)

Antibiotic treatment

   

0.110

 Single antibiotic

120 (36.0)

69 (40.4)

51 (31.5)

 Combined antibiotics

213 (64.0)

102 (59.6)

111 (68.5)

Time to start antibiotic

   

0.125

 Early (within 24 h)

307 (91.1)

163 (93.7)

144 (88.3)

 

 Late (>24 h)

30 (8.9)

11 (6.3)

19 (11.7)

Empirical antibiotic treatment

   

<0.001

 Appropriate

212 (62.9)

133 (76.4)

79 (48.5)

 Inappropriate

125 (37.1)

41 (23.6)

84 (51.5)

  1. DS drug-sensitive, MDR multidrug-resistant, XDR extensively drug-resistant, PDR pandrug-resistant A. baumannii, MRSA methicillin-resistant Staphylococcus aureus.
  2. aOthers including E. coli, S. maltophilia, H. influenzae, methicillin-sensitive Staphylococcus aureus, and Enterococcus spp.